Home › Funds › Saturn V Capital Management LP › XFOR
Saturn V Capital Management LP position in XFOR
X4 PHARMACEUTICALS INC · Health Care
Saturn V Capital Management LP reported holding 7,366,442 shares of XFOR (X4 PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$21.4M, representing 3.13% of its reported portfolio and ranking #13 among its reported holdings. Saturn V Capital Management LP has disclosed XFOR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Saturn V Capital Management LP's XFOR position evolved
Saturn V Capital Management LP first disclosed a stake in XFOR in Q4 2025 at 5,800,530 shares (US$23.2M). The position peaked in Q2 2026 at 6,973,343 shares, worth US$32.6M. Across 4 filings, Saturn V Capital Management LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 7,366,442 shares valued at US$21.4M — an increase of 393,099 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 5.80M | $23.20M | New |
| Q1 2026 | 6.46M | $26.67M | Add |
| Q2 2026 | 6.97M | $32.57M | Add |
| Q3 2026 | 7.37M | $21.36M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XFOR and 13F data
XFOR (X4 PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in XFOR — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$37.0M), Empery Asset Management, LP (US$28.2M), Bain Capital Life Sciences Investors, LLC (US$23.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XFOR
- PERCEPTIVE ADVISORS LLC 7.93M sh · $37.05M · Q2 2026
- Empery Asset Management, LP 9.73M sh · $28.20M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 7.97M sh · $23.11M · Q3 2026
- NEA Management Company, LLC 3.23M sh · $15.10M · Q2 2026
- Kalehua Capital Management LLC 3.72M sh · $10.80M · Q3 2026
- BVF INC/IL 2.23M sh · $10.43M · Q2 2026
- Rosalind Advisors, Inc. 3.21M sh · $9.32M · Q3 2026
- Venrock Adviser, LLC 1.93M sh · $9.03M · Q2 2026
- Trails Edge Capital Partners, LP 2.57M sh · $7.46M · Q3 2026
- Samsara BioCapital, LLC 1.40M sh · $6.52M · Q2 2026
- Verdad Advisers, LP 323.17K sh · $937.18K · Q3 2026
More on Saturn V Capital Management LP
FAQ
How long has Saturn V Capital Management LP held XFOR?
Saturn V Capital Management LP has disclosed XFOR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Saturn V Capital Management LP's current position in XFOR?
As of Q3 2026, Saturn V Capital Management LP holds 7.37M shares of XFOR (X4 PHARMACEUTICALS INC), valued at $21.36M, representing 3.13% of its reported portfolio and ranking #13.
Has Saturn V Capital Management LP been buying or selling XFOR?
In the latest 13F filing (Q3 2026), Saturn V Capital Management LP increased its position in XFOR. The position peaked in Q2 2026 at 6.97M shares.
Which other funds hold XFOR?
Other major institutional holders of XFOR include PERCEPTIVE ADVISORS LLC, Empery Asset Management, LP, Bain Capital Life Sciences Investors, LLC, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.